Liver Cancer and Alcohol

Clinics in Liver Disease

Volumn 16, Issue 4, 2012, Pages 839-850

  Grewal, Priya ^a   Viswanathen, Vijay Anand ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohol; Diabetes mellitus; Hepatitis C; Liver cancer; Obesity; Pathogenesis; Smoking

Indexed keywords

AFLATOXIN B1; ALCOHOL; ALPHA FETOPROTEIN; CARCINOGEN;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; CANCER GROWTH; CANCER RISK; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DNA DAMAGE; DRINKING BEHAVIOR; ECHOGRAPHY; FATTY LIVER; GENE EXPRESSION; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; IRON OVERLOAD; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER INJURY; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; OBESITY; OUTCOME ASSESSMENT; PATHOGENESIS; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SMOKING; TOBACCO; ULTRASOUND; UNITED STATES; VIRUS HEPATITIS;

ALCOHOL DRINKING; ALCOHOLISM; CARCINOMA, HEPATOCELLULAR; DIABETES COMPLICATIONS; ETHANOL; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IRON OVERLOAD; LIVER CIRRHOSIS, ALCOHOLIC; LIVER DISEASES; LIVER NEOPLASMS; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; SMOKING;

EID: 84867961769     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.08.011     Document Type: Review

References (84)

1. Ferlay J., Bray F., Pisani P., et al. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0 2001, International Agency for Research on Cancer CancerBase no. 5, IARC Press, Lyon (France).
2. Surveillance, epidemiology, and End results (SEER) Program. SEER*Stat database: incidence - SEER 9 Regs research data, Nov 2009 Sub (1973-2007) 2010, National Cancer Institute, Bethesda (MD).
3. World Health Organization, International Agency for Research on Cancer. GLOBOCAN 2008. Available at: http://globocan.iarc.fr.
4. Grant B., Harford T., Dawson D., et al. Prevalence of DSM-IV alcohol abuse and dependence United States, 1992. Alcohol Health Res World 1994, 18:243-248.
5. Alcoholic beverage consumption and ethyl caramate (urethane). IARC monographs on the evaluation of carcinogenic risks to humans 96. Lyon: International Agency for Research on Cancer.
6. IARC. Preamble to the IARC monographs on the evaluation of carcinogenic risks to humans. Available at: http://monographs.iarc.fr/ENG/Preamble/CurrentPreamble.pdf.
7. Wu D., Cederbaum A.I. Alcohol, oxidative stress, and free radical damage. Alcohol Res Health 2003, 27(4):277-284.
8. Donato F., Tagger A., Gelatti U., et al. Alcohol and hepatocellular carcinoma the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002, 155:323-331.
9. Bagnardi V., Blangiardo M., La Vecchia C., et al. A meta-analysis of alcohol drinking and cancer risk. Br J Cancer 2001, 85(11):1700-1705.
10. Dong C., Yoon Y.H., Chen C.M., et al. Heavy alcohol use and premature death from hepatocellular carcinoma in the United States, 1999-2006. J Stud Alcohol Drugs 2011, 72(6):892-902.
11. Trichopoulos D., Bamia C., Lagiou P., et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst 2011, 103(22):1686-1695.
12. Yang J.D., Harmsen W.S., Slettedahl S.W., et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol 2011, 9:617-623.
13. Marrero J.A., Fontana R.J., Fu S., et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005, 42:218-224.
14. Corrao G., Bagnardi V., Zambon A., et al. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med 2004, 38:613-619.
15. Shimazu T., Sasazuki S., Wakai K., et al. Alcohol drinking and primary liver cancer: a pooled analysis of four Japanese cohort studies. Int J Cancer 2012, 130(11):2645-2653.
16. Heckley G.A., Jarl J., Asamoah B.O., et al. How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature. BMC Cancer 2011, 11:446.
17. Fong T.L., Kanel G.C., Conrad A., et al. Clinical significance of concomitant hepatitis C infection in patients with alcoholic liver disease. Hepatology 1994, 19:554-557.
18. Gonzalez-Quintela A., Alende R., Aguilera A., et al. Hepatitis C virus antibodies in alcoholic patients. Rev Clin Esp 1995, 195:367-372.
19. Zignego A.L., Foschi M., Laffi G., et al. "Inapparent" hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease. Hepatology 1994, 19:577-582.
20. Oshita M., Hayashi N., Kasahara A., et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis. Hepatology 1994, 20:1115-1120.
21. Befrits R., Hedman M., Blomquist L. Chronic hepatitis C in alcoholic patients: prevalence, genotypes, and correlation to liver disease. Scand J Gastroenterol 1995, 30:1113-1118.
22. Mendenhall C.L., Moritz T., Rouster S., et al. Epidemiology of hepatitis C among veterans with alcoholic liver disease. Am J Gastroenterol 1993, 88:1022-1026.
23. Poynard, Bedossa, Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C; for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC group. Lancet 1997, 349:825-832.
24. Berman K., Tandra S., Vuppalanch R., et al. Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study. Am J Gastroenterol 2011, 106:899-906.
25. Miyakawa H., Sato C., Tazawa J., et al. A prospective study on hepatocellular carcinoma in liver cirrhosis respective roles of alcohol and hepatitis C virus infection. Alcohol Alcohol Suppl 1994, 29(1):75-79.
26. Shimauchi Y., Tanaka M., Koga K., et al. Clinical characteristics of patients in their 40s with HCV antibody-positive hepatocellular carcinoma. Alcohol Clin Exp Res 2000, 24:64S-67S.
27. Okada S., Ishii H., Nose H., et al. Effect of heavy alcohol intake on long-term results after curative resection of hepatitis C virus-related hepatocellular carcinoma. Jpn J Cancer Res 1996, 87:867-873.
28. Kubo S., Kinoshita H., Hirohashi K., et al. High malignancy of hepatocellular carcinoma in alcoholic patients with hepatitis C virus. Surgery 1997, 121:425-429.
29. Zhu G.T., Lou G.Q., Shi J.P. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2011, 25(5):328-330. [in Chinese].
30. Kwon O.S., Jung Y.K., Kim Y.S., et al. Effect of alcohol on the development of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis: a cross-sectional case-control study. Korean J Hepatol 2010, 16:308-314.
31. Kuper H., Tzonou A., Kaklamani E., et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000, 85:498-502.
32. Shih W.L., Chang H.C., Liaw Y.F., et al. Influences of tobacco and alcohol use on hepatocellular carcinoma survival. Int J Cancer 2012, 10.1002/ijc.27508.
33. Staretz M.E., Murphy S.E., Patten C.J., et al. Comparative metabolism of the tobacco-related carcinogens benzo[a]pyrene, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and N'- nitrosonornicotine in human hepatic microsomes. Drug Metab Dispos 1997, 25:154-162.
34. Yuan J.M., Govindarajan S., Arakawa K., et al. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer 2004, 101(5):1009-1017.
35. Balbi M., Donadon V., Ghersetti M., et al. Alcohol and HCV chronic infection are risk cofactors of type 2 diabetes mellitus for hepatocellular carcinoma in Italy. Int J Environ Res Public Health 2010, 7:1366-1378.
36. Loomba R., Yang H.I., Su J., et al. Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin Gastroenterol Hepatol 2010, 8(10):891-898.
37. N'Kontchou G., Paries J., Htar M.T., et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 2006, 4:1062-1068.
38. Ganne-Carrie N., Christidis C., Chastang C., et al. Liver iron is predictive of death in alcoholic cirrhosis: a multivariate study of 229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis: a prospective follow up study. Gut 2000, 46:277-282.
39. Nahon P., Sutton A., Rufat P., et al. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 2008, 134:102-110.
40. Lauret E., Rodríguez M., González S., et al. HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. Am J Gastroenterol 2002, 97:1016-1021.
41. Scotet V., Mérour M.C., Mercier A.Y., et al. Hereditary hemochromatosis: effect of excessive alcohol consumption on disease expression in patients homozygous for the C282Y mutation. Am J Epidemiol 2003, 158:129-134.
42. Cauza E., Peck-Radosavljevic M., Ulrich-Pur H., et al. Mutations of the HFE gene in patients with hepatocellular carcinoma. Am J Gastroenterol 2003, 98:442-447.
43. Boige V., Castéra L., de Roux N., et al. Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosis. Gut 2003, 52:1178-1181.
44. Bulatao-Jayme J., Almero E.M., Castro C.A., et al. A case-control dietary study of primary liver cancer risk from aflatoxin exposure. Int J Epidemiol 1982, 11:112-119.
45. Tamburro C.H., Lee H.M. Primary hepatic cancer in alcoholics. Clin Gastroenterol 1981, 10:457-477.
46. Gemma S., Vichi S., Testai E. Individual susceptibility and alcohol effects: biochemical and genetic aspects. Ann Ist Super Sanita 2006, 42(1):8-16.
47. Norberg A., Jones A.W., Hahn R.G., et al. Role of variability in explaining ethanol pharmacokinetics: research and forensic applications. Clin Pharmacokinet 2003, 42(1):1-31.
48. Crabb D.W., Liangpunsakul S. Acetaldehyde generating enzyme systems: roles of alcohol dehydrogenase, CYP2E1 and catalase, and speculations on the role of other enzymes and processes. Novartis Found Symp 2007, 285:4-16. [discussion: 16-22].
49. Eriksson C.J. The role of acetaldehyde in the actions of alcohol (update 2000). Alcohol Clin Exp Res 2001, 25(Suppl):15S-32S.
50. Seitz H.K., Becker P. Alcohol metabolism and cancer risk. Alcohol Res Health 2007, 30(1):38-41.
51. Tuma D.J., Casey C.A. Dangerous byproducts of alcohol breakdown-focus on adducts. Alcohol Res Health 2003, 27(4):285-290.
52. Zakhari S. Overview: how is alcohol metabolized by the body?. Alcohol Res Health 2006, 29(4):245-254.
53. Deitrich R.A., Petersen D., Vasiliou V. Removal of acetaldehyde from the body. Novartis Found Symp 2007, 285:23-40. [discussion: 40-51].
54. Homann N., Stickel F., Konig I.R., et al. Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Int J Cancer 2006, 118(8):1998-2002.
55. Cederbaum A.I. CYP2E1-biochemical and toxicological aspects and role in alcohol-induced liver injury. Mt Sinai J Med 2006, 73(4):657-672.
56. Das S.K., Vasudevan D.M. Alcohol-induced oxidative stress. Life Sci 2007, 81(3):177-187.
57. Konishi M., Ishii H. Role of microsomal enzymes in development of alcoholic liver diseases. J Gastroenterol Hepatol 2007, 22(Suppl 1):S7-S10.
58. Lu Y., Cederbaum A.I. CYP2E1 and oxidative liver injury by alcohol. Free Radic Biol Med 2008, 44(5):723-738.
59. Lieber C.S., DeCarli L.M. The role of the hepatic microsomal ethanol oxidizing system (MEOS) for ethanol metabolism in vivo. J Pharmacol Exp Ther 1972, 181(2):279-287.
60. Badger T.M., Ronis M.J., Seitz H.K., et al. Alcohol metabolism: role in toxicity and carcinogenesis. Alcohol Clin Exp Res 2003, 27(2):336-347.
61. Koop D.R. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J 1992, 6(2):724-730.
62. Zima T., Kalousova M. Oxidative stress and signal transduction pathways in alcoholic liver disease. Alcohol Clin Exp Res 2005, 29(Suppl 11):110S-115S.
63. Baan R., Straif K., Grosse Y., et al. Carcinogenicity of alcoholic beverages. Lancet Oncol 2007, 8(4):292-293.
64. Brooks P.J., Theruvathu J.A. DNA adducts from acetaldehyde: implications for alcohol-related carcinogenesis. Alcohol 2005, 35(3):187-193.
65. Lenaz G. The mitochondrial production of reactive oxygen species: mechanisms and implications in human pathology. IUBMB Life 2001, 52(3-5):159-164.
66. Tanaka E., Terada M., Misawa S. Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther 2000, 25(3):165-175.
67. Vaca C.E., Fang J.L., Schweda E.K. Studies of the reaction of acetaldehyde with deoxynucleosides. Chem Biol Interact 1995, 98(1):51-67.
68. Lieber C.S. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 1997, 77(2):517-544.
69. Lieber C.S. ALCOHOL: its metabolism and interaction with nutrients. Annu Rev Nutr 2000, 20:395-430.
70. Guengerich F.P., Shimada T., Yun C.H., et al. Interactions of ingested food, beverage, and tobacco components involving human cytochrome P4501A2, 2A6, 2E1, and 3A4 enzymes. Environ Health Perspect 1994, 102(Suppl 9):49-53.
71. Yang C.S., Yoo J.S., Ishizaki H., et al. Cytochrome P450IIE1: roles in nitrosamine metabolism and mechanisms of regulation. Drug Metab Rev 1990, 22(2-3):147-159.
72. Nagata K., Suzuki H., Sakaguchi S. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J Toxicol Sci 2007, 32(5):453-468.
73. Thurman R.G. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 1998, 275(4 Pt 1):G605-G611.
74. Bode C., Bode J.C. Activation of the innate immune system and alcoholic liver disease: effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol. Alcohol Clin Exp Res 2005, 29(Suppl):166S-171S.
75. Hoek J.B., Pastorino J.G. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol 2002, 27(1):63-68.
76. Hoek J.B., Pastorino J.G. Cellular signaling mechanisms in alcohol-induced liver damage. Semin Liver Dis 2004, 24(3):257-272.
77. Roberts R.A., Ganey P.E., Ju C., et al. Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci 2007, 96(1):2-15.
78. Thakur V., McMullen M.R., Pritchard M.T., et al. Regulation of macrophage activation in alcoholic liver disease. J Gastroenterol Hepatol 2007, 22(Suppl 1):S53-S56.
79. Ruttinger D., Vollmar B., Wanner G.A., et al. In vivo assessment of hepatic alterations following gadolinium chloride-induced Kupffer cell blockade. J Hepatol 1996, 25(6):960-967.
80. Vollmar B., Ruttinger D., Wanner G.A., et al. Modulation of Kupffer cell activity by gadolinium chloride in endotoxemic rats. Shock 1996, 6(6):434-441.
81. Albano E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol Aspects Med 2008, 29(1-2):9-16.
82. Lirussi F., Azzalini L., Orando S., et al. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007, (1). CD004996.
83. Yang X., Lu P., Ishida Y., et al. Attenuated liver tumor formation in the absence of CCR2 with a concomitant reduction in the accumulation of hepatic stellate cells, macrophages and neovascularization. Int J Cancer 2006, 118(2):335-345.
84. Bruix J., Sherman M. AASLD practice guideline for management of HCC. Hepatology 2011, 53(3):1020-1022.